Cervical cancer prevention in Australia: an evolving process towards elimination

Abstract

Australia established a National Cervical Screening Programme (NCSP) in 1991 using the Papanicolaou smear on a 2 -yearly interval. This led to an initial drop in cervical cancer incidence, mainly of the squamous origin, but has plateaued since 2007. Introduction of a National HPV Vaccination Program for girls in 2007, which now includes boys, was followed by a major change in the NCSP to a 5-yearly cervical screening for people aged 25-74, using a primary human papillomavirus (HPV) test with partial HPV genotyping and reflex liquid-based cytology triage, designated as a Cervical Screening Test. The next important milestone was expanding the option of self-collection to all eligible people in 2022 to encourage more participation in cervical screening. Population-based cancer screening programmes require monitoring of their performance, quality and safety. NCSP monitoring reports are produced annually with performance indicators grouped under each of the five population screening pathway stages of 'Recruitment', 'Screening', 'Assessment', 'Diagnosis' and 'Outcomes'. From this monitoring, changes are being made in the renewed NCSP Guidelines to improve participation and management of screened abnormalities. All this is underpinned by the provision of cervical screening data by the National Cancer Screening Register. In 2020, WHO published the Global Strategy for cervical cancer elimination with goals to achieve through HPV vaccination, screening with a high-performance test and women identified with cervical disease receiving treatment. Australia has made good progress in 2023 with 84.2% HPV vaccine coverage for girls by the age of 15 years, 82.8% of women aged 35-39 screened at least once with an HPV test and 79.8% of women aged 45-49 having been screened at least twice, and 84.5% and 88.7% of those with precancer detected in 2022 were treated within 6 and 12 months.

Contributors This is a personal review on the evolving process towards elimination of Cervical Cancer in Australia, which includes reports from the NCSP, AlHW and NHMRC that are available in the public domain and duly referenced.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests None declared.

Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

Patient consent for publication Not applicable.

Ethics approval Not applicable.

Provenance and peer review Not commissioned; externally peer reviewed.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See https://creativecommons.org/licenses/by-nc/4.0/.

ORCID iD

Jeffrey Heow Joo Tan https://orcid.org/0000-0002-0226-8647

References

[1] Medical Services Advisory Committee. National cervical screening program renewal: effectiveness modelling and economic evaluation in the Australian setting. report November 2013. MSAC application 1276. Canberra:Australian Government Department of Health; 2014. Available: https://www.msac.gov.au/sites/default/files/documents/1276%2520-%2520Final%2520MSAC%2520PSD%2520-%2520NCSP%2520Renewal.pdf

[2] Global strategy to accelerate the elimination of cervical cancer as a public health problem. World Health Organization, 2020.

[3] Brotherton J, Machalek D, Smith M, et al. Cervical cancer elimination progress report: Australia's progress towards the elimination of cervical cancer as a public health problem. Melbourne, Australia, 2025. Available: https://www.cervicalcancercontrol.org.au

[4] Australian Institute of Health and Welfare (AIHW). Cancer data in Australia. 2025. Available: www.aihw.gov.au/reports/cancer/cancer-data-in-australia

[5] Australian Institute of Health and Welfare. National cervical screening program monitoring report 2024. catalogue number CAN 163. AIHW, Australian Government; 2024.

[6] Human-papillomavirus-hpv-immunisation-data. 2025 Available: https://www.health.gov.au/topics/immunisation/immunisation-data/human-papillomavirus-hpv-immunisation-data

[7] Smith MA, Whop LJ, Brotherton J. Cervical cancer elimination: true success requires equity. 2023. Available: https://www.hpvworld.com/articles/cervical-cancer-elimination-true-success-requires-equity/

[8] Impact evaluation of Australian national human papillomavirus vaccination program final report February 2021. National Centre for Immunisation Research and Surveillance; 2021. Available: https://ncirs.org.au/sites/default/files/2021-11/Impactevaluation%20of%20national%20HPV%20vaccination%20program_February%202021%20Report_0.pdf

[9] Muñoz N, Bosch FX, de Sanjosé S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003; 348:518-27.

[10] National Pathology Accreditation Advisory Council (NPAAC). 2025 Available: https://www.safetyandquality.gov.au/our-work/accreditation/pathology-accreditation-standards/national-pathology-accreditation-advisory-council

[11] National cervical screening program guidelines for the management of screen-detected abnormalities, screening in specific populations and investigation of abnormal vaginal bleeding. 2025 Available: https://app.magicapp.org/#/guideline/Eez2Kj

[12] National cancer screening register. 2025 Available: www.ncsr.gov.au

[13] National cancer screening register rules 2017. 2025 Available: https://www.legislation.gov.au/F2017L01547/latest/text

[14] Colposcopy and treatment form. Available: https://www.health.gov.au/sites/default/files/2025-12/national-cervical-screening-program-colposcopy-and-treatment-form.pdf

[15] Australian Institute of Health and Welfare. National cervical screening program monitoring report 2025, catalogue number CAN 166. AIHW, Australian Government; 2025.

[16] Tabrizi SN, Brotherton JML, Kaldor JM, et al. Assessment of herd immunity and cross-protection after a human papillomavirus vaccination programme in Australia: a repeat cross-sectional study. Lancet Infect Dis 2014; 14:958-66.

[17] Australian Institute of Health and Welfare. Cervical screening in Australia 2014-2015. Canberra AIHW; 2017.

[18] Hall MT, Simms KT, Lew J-B, et al. Projected future impact of HPV vaccination and primary HPV screening on cervical cancer rates from 2017-2035: Example from Australia. PLoS One 2018; 13:e0185332.

[19] Australian Institute of Health and Welfare. National cervical screening program monitoring report 2020. cancer series 130. cat. no.CAN 138. AIHW; 2020.

[20] Chin FHX, Wrede CDH, Richards A, et al. Primary HPV cervical screening: Clinical audit of outcomes of women seen at a tertiary referral centre for colposcopy in Australia. Aust NZ J Obst Gynaeco 2021; 61:750-8.

[21] Schaafsma M, Schuurman TN, van Maurik IS, et al. Optimal followup strategy using high-risk human papillomavirus testing and cytology after conservative treatment for cervical adenocarcinoma in situ. Am J Obstet Gynecol 2025; 233:459.

[22] Smith M, Hammond I, Saville M. Lessons from the renewal of the National Cervical Screening Program in Australia. Public Health Res Pract 2019; 29:2921914.

[23] Gottschlich A, Gondara L, Smith LW, et al. Colposcopy referral rates post-introduction of primary screening with human papillomavirus testing: evidence from a large British Columbia cohort study. Lancet Reg Health Am 2023; 26:100598.

[24] Smith MA, Sherrah M, Sultana F, et al. National experience in the first two years of primary human papillomavirus (HPV) cervical screening in an HPV vaccinated population in Australia: observational study. BMJ 2022; 376:e068582.

[25] Tan JHJ, Jones A, Steele A, et al. Diagnostic outcomes after colposcopy at a tertiary clinic for women aged 50-74 referred after detection of oncogenic human papillomavirus at primary screening. Aust NZ J Obst Gynaeco 2023; 63:564-70.

[26] Cervical screening test self-collection uptake report as of 22nd April 2025. Available: https://www.health.gov.au/resources/publications/update-on-cervical-screening-self-collection-uptake?language=en

[27] Lee A, Hawkes D, Sweeney D, et al. Exponential uptake of HPV self-collected cervical screening testing 2 years since universal availability in Victoria, Australia. BMC Med 2025; 23:389.

[28] World Health Organization. WHO guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention: use of dual-stain cytology to triage women after a positive test for human papillomavirus (HPV). 2024 Available: https://www.who.int/publications/i/item/9789240091658

[29] Dick S, Heideman DAM, Berkhof J, et al. Clinical indications for hostcell DNA methylation markers in cervical screening and management of cervical intraepithelial neoplasia: A review. Tumour Virus Res 2025; 19:200308.

[30] Liu L, Liu J, Su Q, et al. Performance of artificial intelligence for diagnosing cervical intraepithelial neoplasia and cervical cancer: a systematic review and meta-analysis. EClinicalMedicine 2025; 80:102992.

[31] Cheng L, Wang R, Yan J. A review of urinary HPV testing for cervical cancer management and HPV vaccine surveillance: rationale, strategies, and limitations. Eur J Clin Microbiol Infect Dis 2024; 43:2247-58.